Coverage Guidances
In Oregon's Action Plan for Health, the Oregon Health Policy Board calls for the development of an initial set of 10 Oregon-based best practice guidelines and standards. The intent is to build upon the high standards of evidence evaluation used in the development of guidelines and health technology assessments by HERC and other trusted sources, creating a process that will allow evidence-based practices to be applied rapidly and uniformly across public and private settings to reduce unnecessary care and drive down costs.
HERC Coverage Guidance Process
To view the steps of each phase of the Coverage Guidance process, click on the tabs below:
- Staff Research
Staff conducts research to identify new topics based on reports from trusted resources.
- Prioritize Topics
Based on staff recommendations, HERC to prioritize topics and assign to the Evidence-based Guidelines Subcommittee (EbGS) or the Health Technology Assessment Subcommittee (HTAS).
Follow topic prioritization in HERC meeting materials.
- Assessment
Notice is sent to stakeholders at least 30 days prior to initial review by either the EBGS or HTAS.
- Announcement
Notice is sent to stakeholders at least 30 days prior to initial review by either the EBGS or HTAS.
Recieve notices by e-Subscribing to the HERC list.
- Prepare Initial Draft
Staff develops draft coverage guidance, with input from appointed ad hoc experts if necessary.
Initial draft is posted to the EbGS or HTAS meetings materials page at least 7 days prior to initial review.
- Initial Review
The subcommittee reviews the initial draft at a public meeting and votes to post the guidance for a public comment period. The subcommittee can also opt to revise the draft, request additional information, or table to discuss – in which case the initial draft would require another review before moving to public comment.
This is a public meeting. Oral comment is accepted at public meetings but may be limited to 5 minutes per topic shared among those who comment.
- Public Comment
The draft guidance approved by the subcommittee is posted online for 30 days of public comment.
*Written comments can be submitted to HERC.info@state.or.us. Comments are limited to 1000 words not including any citations or articles.
- Staff Research
Based on public comment, staff research, draft responses and propose revisions to the draft guidance.
- Review Public Comment
The subcommittee reviews public comments and staff responses. The subcommittee may revise the guidance and repost for an additional 21-day public comment period – in which case the draft guidance would return to the staff research step.
* This is a public meeting.
- Refer to Value-based Benefits Subcommittee
Once the public comment review is finished, the subcommittee holds a public meeting and votes to refer the draft to the Value-based Benefits Subcommittee (VbBS).
- VbBS Review
VbBS reviews the draft guidance. They may recommend revisions for implementation and prioritization considerations – in which case the draft guidance would return to the staff research step of the coverage guidance process and could be posted for an additional 21-day public comment period if the revisions are significant.
* This is a public meeting.
- HERC Review
HERC considers the guidance for final approval.
* This is a public meeting.
- Staff Monitoring
HERC reviews the need to update each approved guidance once every two years. If a topic is determined as needing review, this process starts over at step two of the coverage guidance process – prioritizing the topic. Reviews may be initiated at any time and may be requested by interested stakeholders if they feel new evidence hasn’t been considered or existing evidence has been misinterpreted.
Evidence-based Policy Presentation
This presentation, What Is Evidence-informed Health Policymaking, by Martha Gerrity from the Center for Evidence-based Policy (CEbP) at Oregon Health and Sciences University (OHSU), discusses the use of evidence for making health policy decisions. Methods of analyzing evidence (e.g., systematic reviews, randomized controlled trials, observational studies) to determine its quality are described. Also discussed are key questions which should be asked when reviewing evidence.
This presentation was made to the Health Technology Assessment Subcommittee of the HERC on March 22, 2012. This video is being posted for use by the HERC and its subcommittees as well others who might benefit from a primer on this topic.